| abstract |
Children's dosage forms have been proposed for use in the treatment of cholestatic liver diseases in children by non-systemic administration to the patient of a therapeutically effective amount of the infant dosage form containing an inhibitor of an apical sodium-dependent bile acid transporter (ASBTI) or its therapeutically acceptable salt. These children's dosage forms have also been proposed for use in the treatment of liver diseases in children for reducing the bile acid content in serum or liver, treating pruritus, reducing the content of liver enzymes or bilirubin, including non-systemic administration to the patient of a therapeutically effective amount of a child preparation containing ASBTI or its therapeutically acceptable salt. |